Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Mar;83(3):466–471. doi: 10.1111/j.1365-2249.1991.tb05662.x

Modulation of Mycobacterium avium growth in vivo by cytokines: involvement of tumour necrosis factor in resistance to atypical mycobacteria.

M Denis 1
PMCID: PMC1535333  PMID: 1900745

Abstract

The protective mechanisms associated with resistance to atypical mycobacteria infections are not clear. In an effort to broaden our understanding of the mechanisms involved, susceptible mice were infected with a virulent strain of M. avium and various treatments were applied so as to modify the course of the disease. Treatment with an antiserum against tumour necrosis factor-alpha (TNF-alpha) significantly enhanced the experimental infection, as judged by enumeration of colony-forming units (CFU) in the spleens and livers of infected mice, suggesting a role for TNF-alpha in resistance to M. avium. In other sets of experiments, recombinant cytokines were directly infused into infected mice. Infusion of recombinant interferon-gamma (IFN-gamma) did not modify the experimental infection significantly, and infusion of interleukin-2 was also without effect. Injection of TNF-alpha enhanced resistance in susceptible animals, as seen by a reduction in the viable bacilli recovered from the spleens and livers. In a final set of experiments, we demonstrate that combinations of cytokines may induce strong resistance against M. avium, namely injection of 1 micrograms of interleukin-1 alpha and 1 micrograms of TNF-alpha at 5-day intervals which was seen to eradicate M. avium in both spleens and livers of susceptible BALB/c mice. Overall, our results suggest that induction of protection against M. avium by treatment with cytokines may be feasible, and that TNF-alpha may be a pivotal molecule in resistance to M. avium.

Full text

PDF
466

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banerjee D. K., Sharp A. K., Lowrie D. B. The effect of gamma-interferon during Mycobacterium bovis (BCG) infection in athymic and euthymic mice. Microb Pathog. 1986 Apr;1(2):221–224. doi: 10.1016/0882-4010(86)90024-0. [DOI] [PubMed] [Google Scholar]
  2. Bermudez L. E., Kolonoski P., Young L. S. Natural killer cell activity and macrophage-dependent inhibition of growth or killing of Mycobacterium avium complex in a mouse model. J Leukoc Biol. 1990 Feb;47(2):135–141. doi: 10.1002/jlb.47.2.135. [DOI] [PubMed] [Google Scholar]
  3. Bermudez L. E., Stevens P., Kolonoski P., Wu M., Young L. S. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol. 1989 Nov 1;143(9):2996–3000. [PubMed] [Google Scholar]
  4. Bermudez L. E., Young L. S. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol. 1988 May 1;140(9):3006–3013. [PubMed] [Google Scholar]
  5. Chang H. R., Grau G. E., Pechère J. C. Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology. 1990 Jan;69(1):33–37. [PMC free article] [PubMed] [Google Scholar]
  6. Crowle A. J., Tsang A. Y., Vatter A. E., May M. H. Comparison of 15 laboratory and patient-derived strains of Mycobacterium avium for ability to infect and multiply in cultured human macrophages. J Clin Microbiol. 1986 Nov;24(5):812–821. doi: 10.1128/jcm.24.5.812-821.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Denis M., Chadee K. Murine T-cell clones against Entamoeba histolytica: in vivo and in vitro characterization. Immunology. 1989 Jan;66(1):76–82. [PMC free article] [PubMed] [Google Scholar]
  8. Denis M., Forget A., Pelletier M., Turcotte R., Skamene E. Control of the Bcg gene of early resistance in mice to infections with BCG substrains and atypical mycobacteria. Clin Exp Immunol. 1986 Mar;63(3):517–525. [PMC free article] [PubMed] [Google Scholar]
  9. Donohue J. H., Rosenberg S. A. The fate of interleukin-2 after in vivo administration. J Immunol. 1983 May;130(5):2203–2208. [PubMed] [Google Scholar]
  10. Douvas G. S., Looker D. L., Vatter A. E., Crowle A. J. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun. 1985 Oct;50(1):1–8. doi: 10.1128/iai.50.1.1-8.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Edwards C. K., 3rd, Hedegaard H. B., Zlotnik A., Gangadharam P. R., Johnston R. B., Jr, Pabst M. J. Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J Immunol. 1986 Mar 1;136(5):1820–1827. [PubMed] [Google Scholar]
  12. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  13. Granelli-Piperno A., Andrus L., Steinman R. M. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med. 1986 Apr 1;163(4):922–937. doi: 10.1084/jem.163.4.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Haak-Frendscho M., Young K. M., Czuprynski C. J. Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes. Infect Immun. 1989 Oct;57(10):3014–3021. doi: 10.1128/iai.57.10.3014-3021.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Havell E. A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol. 1989 Nov 1;143(9):2894–2899. [PubMed] [Google Scholar]
  16. Jeevan A., Asherson G. L. Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice. Lymphokine Res. 1988 Summer;7(2):129–140. [PubMed] [Google Scholar]
  17. Kaufmann S. H., Flesch I. E. Antimycobacterial functions in bone-marrow-derived macrophages. Res Microbiol. 1990 Feb;141(2):244–248. doi: 10.1016/0923-2508(90)90038-r. [DOI] [PubMed] [Google Scholar]
  18. Kindler V., Sappino A. P., Grau G. E., Piguet P. F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989 Mar 10;56(5):731–740. doi: 10.1016/0092-8674(89)90676-4. [DOI] [PubMed] [Google Scholar]
  19. Koff W. C., Fann A. V. Human tumor necrosis factor-alpha kills herpesvirus-infected but not normal cells. Lymphokine Res. 1986 Summer;5(3):215–221. [PubMed] [Google Scholar]
  20. Liew F. Y., Parkinson C., Millott S., Severn A., Carrier M. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology. 1990 Apr;69(4):570–573. [PMC free article] [PubMed] [Google Scholar]
  21. Malkovský M., Loveland B., North M., Asherson G. L., Gao L., Ward P., Fiers W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987 Jan 15;325(6101):262–265. doi: 10.1038/325262a0. [DOI] [PubMed] [Google Scholar]
  22. Mor N., Goren M. B., Crowle A. J. Enhancement of growth of Mycobacterium lepraemurium in macrophages by gamma interferon. Infect Immun. 1989 Aug;57(8):2586–2587. doi: 10.1128/iai.57.8.2586-2587.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nakane A., Minagawa T., Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988 Oct;56(10):2563–2569. doi: 10.1128/iai.56.10.2563-2569.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. O'Brien R. J., Geiter L. J., Snider D. E., Jr The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis. 1987 May;135(5):1007–1014. doi: 10.1164/arrd.1987.135.5.1007. [DOI] [PubMed] [Google Scholar]
  25. Oppenheim J. J., Shneyour A., Kook A. I. Enhancement of DNA synthesis and cAMP content of mouse thymocytes by mediator(s) derived from adherent cells. J Immunol. 1976 May;116(5):1466–1472. [PubMed] [Google Scholar]
  26. Prince D. S., Peterson D. D., Steiner R. M., Gottlieb J. E., Scott R., Israel H. L., Figueroa W. G., Fish J. E. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989 Sep 28;321(13):863–868. doi: 10.1056/NEJM198909283211304. [DOI] [PubMed] [Google Scholar]
  27. Rastogi N., Frehel C., Ryter A., Ohayon H., Lesourd M., David H. L. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents? Antimicrob Agents Chemother. 1981 Nov;20(5):666–677. doi: 10.1128/aac.20.5.666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Reed S. G. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol. 1988 Jun 15;140(12):4342–4347. [PubMed] [Google Scholar]
  29. Roll J. T., Young K. M., Kurtz R. S., Czuprynski C. J. Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha. Immunology. 1990 Feb;69(2):316–322. [PMC free article] [PubMed] [Google Scholar]
  30. Rook G. A., Champion B. R., Steele J., Varey A. M., Stanford J. L. I-A restricted activation by T cell lines of anti-tuberculosis activity in murine macrophages. Clin Exp Immunol. 1985 Feb;59(2):414–420. [PMC free article] [PubMed] [Google Scholar]
  31. Rook G. A. Progress in the immunology of the mycobacterioses. Clin Exp Immunol. 1987 Jul;69(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  32. Rook G. A., Steele J., Ainsworth M., Champion B. R. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology. 1986 Nov;59(3):333–338. [PMC free article] [PubMed] [Google Scholar]
  33. Rose M. E., Wakelin D., Hesketh P. Gamma interferon controls Eimeria vermiformis primary infection in BALB/c mice. Infect Immun. 1989 May;57(5):1599–1603. doi: 10.1128/iai.57.5.1599-1603.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schellekens H. Animal models in interferon research: some current trends. Experientia. 1989 Jun 15;45(6):558–562. doi: 10.1007/BF01990506. [DOI] [PubMed] [Google Scholar]
  35. Sharma S. D., Hofflin J. M., Remington J. S. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol. 1985 Dec;135(6):4160–4163. [PubMed] [Google Scholar]
  36. Sibley L. D., Krahenbuhl J. L. Induction of unresponsiveness to gamma interferon in macrophages infected with Mycobacterium leprae. Infect Immun. 1988 Aug;56(8):1912–1919. doi: 10.1128/iai.56.8.1912-1919.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Squires K. E., Murphy W. F., Madoff L. C., Murray H. W. Interferon-gamma and Mycobacterium avium-intracellulare infection. J Infect Dis. 1989 Mar;159(3):599–600. doi: 10.1093/infdis/159.3.599. [DOI] [PubMed] [Google Scholar]
  38. Stokes R. W., Collins F. M. Growth of Mycobacterium avium in activated macrophages harvested from inbred mice with differing innate susceptibilities to mycobacterial infection. Infect Immun. 1988 Sep;56(9):2250–2254. doi: 10.1128/iai.56.9.2250-2254.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Titus R. G., Sherry B., Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med. 1989 Dec 1;170(6):2097–2104. doi: 10.1084/jem.170.6.2097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Toba H., Crawford J. T., Ellner J. J. Pathogenicity of Mycobacterium avium for human monocytes: absence of macrophage-activating factor activity of gamma interferon. Infect Immun. 1989 Jan;57(1):239–244. doi: 10.1128/iai.57.1.239-244.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES